Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + docetaxel
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy where dexamethasone is used as a premedication for docetaxel administration to prevent hypersensitivity reactions and fluid retention. Docetaxel is a semisynthetic microtubule inhibitor that arrests the cell cycle and causes apoptosis, while dexamethasone is a corticosteroid that helps reduce adverse reactions to docetaxel.
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dexamethasone + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + docetaxel.